1. A method of fabricating a light emitting device comprising:
growing a crystal layer as a quantum well layer within the light emitting device; and
modulating a process parameter during the growing of the quantum well layer such that the quantum well layer is inhomogeneous and has a non-random, periodic, composition fluctuation across the quantum well layer; and
doping a section of the quantum well layer having a higher bandgap than other sections of the quantum well layer.
2. The method of claim 1, wherein modulating the process parameter comprises alternately increasing and decreasing a flow rate of a metal organic source gas during a metal organic chemical vapor deposition process.
3. The method of claim 2, wherein alternately increasing and decreasing the flow rate of the metal organic source gas comprises alternately starting and stopping the flow rate.
4. The method of claim 1, wherein modulating the process parameter comprises alternately increasing and decreasing a process temperature during a molecular beam epitaxy process.
5. The method of claim 1, wherein modulating the process parameter comprises alternately increasing and decreasing a process pressure during a chemical beam epitaxy process.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound of the formula
wherein the carbon marked with the star is asymmetric whereby the compound has dextrorotatory and levo-rotatory enantiomers.
2. A compound in accordance with claim 1 which is dextro-rotatory.
3. A compound in accordance with claim 1 which is levo-rotatory.
4. A method of activating alpha2B adrenergic receptors in a mammal in need of such activation by administering to the mammal a pharmaceutical composition containing a therapeutically effective dose of a compound in accordance with claim 1.
5. A method of activating alpha2B adrenergic receptors in a mammal in need of such activation by administering to the mammal a pharmaceutical composition containing a therapeutically effective dose of a compound in accordance with claim 2.
6. A method of activating alpha2B adrenergic receptors in a mammal in need of such activation by administering to the mammal a pharmaceutical composition containing a therapeutically effective dose of a compound in accordance with claim 3.
7. A method in accordance with claim 4 where the pharmaceutical composition is administered to the mammal to alleviate pain.
8. A method in accordance with claim 4 where the pharmaceutical composition is administered to the mammal to alleviate chronic pain.
9. A method in accordance with claim 4 where the pharmaceutical composition is administered to the mammal to alleviate allodynia.
10. A method in accordance with claim 4 where the pharmaceutical composition is administered orally.
11. A method in accordance with claim 4 where the pharmaceutical composition is administered intraperitonially.
12. A method in accordance with claim 4 where the mammal is administered the composition for treating a condition selected from the group consisting of chronic pain, visceral pain, neuropathic pain, corneal pain, glaucoma, elevated intraocular pressure, ischemic neuropathies, neurodegenerative diseases, diarrhea, nasal congestion, muscle spasticity, diuresis, withdrawal syndromes, neurodegenerative diseases, optic neuropathy, spinal ischemia, stroke, memory and cognition deficits, attention deficit disorder, psychoses, manic disorders, anxiety, depression, hypertension, congestive heart failure, cardiac ischemia, arthritis, spondylitis, gouty arthritis, osteoarthritis, juvenile arthritis, autoimmune diseases, lupus erythematosus, chronic gastrointestinal inflammations, Crohn’s disease, gastritis, irritable bowel disease (IBD), functional dyspepsia and ulcerative colitis.
13. A method in accordance with claim 12 where the mammal is administered the composition for treating glaucoma.
14. A method in accordance with claim 12 where the mammal is administered the composition for treating neuropathies or neurodegenerative diseases.
15. A method in accordance with claim 12 where the mammal is administered the composition for treating muscle spasticity.